Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japanese Patients With Neovascular AMD (PINE)

NCT03335852 PHASE1 COMPLETED

This study will evaluate the safety and to characterize the systemic pharmacokinetics of free and vascular endothelial growth factor (VEGF)-bound abicipar following multiple monthly intravitreal injections of abicipar in Japanese patients with neovascular age-related macular degeneration (AMD).

Details

Lead sponsor	Allergan
Phase	PHASE1
Status	COMPLETED
Enrolment	11
Start date	Tue Nov 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Oct 08 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Macular Degeneration

Interventions

• Abicipar pegol

Countries

Japan